Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline

Gilead Sciences Inc said on Monday it would buy Forty Seven Inc for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs.